Dr Sharon Poisson, MD | |
12605 E 16th Ave, Aurora, CO 80045-2545 | |
(720) 848-0000 | |
Not Available |
Full Name | Dr Sharon Poisson |
---|---|
Gender | Female |
Speciality | Neurology |
Experience | 20 Years |
Location | 12605 E 16th Ave, Aurora, Colorado |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487771119 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084N0400X | Psychiatry & Neurology - Neurology | A103807 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Colorado Hospital Authority | Aurora, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Lannett Company, Inc. today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals' (formerly Abbott's) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.
Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson's disease will later develop levodopa-induced dyskinesia.
Scientists at St. Jude Children's Research Hospital have teased apart the biological details distinguishing two related neurological diseases-ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).
› Verified 9 days ago
Entity Name | University Physicians Incorporated |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Lannett Company, Inc. today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals' (formerly Abbott's) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.
Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson's disease will later develop levodopa-induced dyskinesia.
Scientists at St. Jude Children's Research Hospital have teased apart the biological details distinguishing two related neurological diseases-ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sharon Poisson, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Dr Sharon Poisson, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Lannett Company, Inc. today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals' (formerly Abbott's) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.
Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson's disease will later develop levodopa-induced dyskinesia.
Scientists at St. Jude Children's Research Hospital have teased apart the biological details distinguishing two related neurological diseases-ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).
› Verified 9 days ago
Lea C Watson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1890 N Revere Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Robert House, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ann Olincy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Paul Moe, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Erin Schwarz, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1537 Alton St, Aurora, CO 80010 Phone: 303-617-2300 | |
Robert Clyman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Bishara Bhasi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |